Skip to main content

Akari Therapeutics Plc

corporate_fare Company Profile

Akari Therapeutics Plc

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed AKTX - Latest Insights

AKTX
Apr 27, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
AKTX
Apr 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
AKTX
Apr 20, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
AKTX
Apr 06, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
AKTX
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
AKTX
Mar 17, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
AKTX
Mar 04, 2026, 4:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
AKTX
Mar 04, 2026, 4:44 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
AKTX
Mar 02, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
AKTX
Feb 03, 2026, 11:15 AM EST
Filing Type: DEF 14A
Importance Score:
9
AKTX
Jan 23, 2026, 5:17 PM EST
Filing Type: S-1
Importance Score:
9
AKTX
Jan 23, 2026, 9:11 AM EST
Filing Type: PRE 14A
Importance Score:
9